Navigation Links
Improvement in Prediction of Blood Clots in Cancer Patients
Date:9/9/2010

WASHINGTON, Sept. 9 /PRNewswire-USNewswire/ -- For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology. VTE, the formation of blood clots in the veins, develops in up to 20 percent of cancer patients and is one of the leading causes of death among this patient population. Patients with hematologic malignancies (blood cancers), particularly those with lymphoma and multiple myeloma, have relatively high rates of VTE—results from this study found that 7.2 percent of lymphoma patients and 7.4 percent of the total study population developed VTE, compared to an estimated general population incidence rate of .001 percent(1)

"Because the risk of VTE is not equal in all cancer patients and anticoagulation in cancer patients results in a higher risk of bleeding complications, categorizing cancer patients according to their VTE risk is important," said Ingrid Pabinger, MD, professor at the Medical University of Vienna and lead author of the study. Patients with high risk of VTE may benefit from routine thrombophrophylaxis, preventive treatment for blood clotting, while low-risk patients tend to have a higher bleeding risk and may not be the best candidates for routine anticoagulation treatments.

Although there is a current risk prediction model for VTE in cancer patients, which includes factors such as site of cancer, body mass index, platelet and leukocyte counts, and hemoglobin level—all known to increase the risk of cancer-associated VTE—the new model also incorporates two new biomarkers, soluble P-selectin (sP-selectin) and D-dimer, to further stratify patients in
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GeneLink Reports Second Quarter Improvement
2. Drug Study Shows Improvement in Major Orthopedic Surgery Care
3. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
4. Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
5. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
6. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
9. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
10. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
11. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 ... of drugs within human and veterinary oncology, has filed ... and Exchange Commission, in connection with the proposed public ... Stock Market. The number of American Depositary Shares, representing ... for the offering have not yet been determined. An ...
(Date:7/7/2015)...  Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing ... and CEO, Chandler D. Robinson MD, MBA, ... Award. The British Council selected one recipient from each ... , and the United States ... who have leveraged their U.K. education in their subsequent ...
(Date:7/7/2015)...   Abide Therapeutics , a developer of ... dosing of the first subject in a Phase ... endocannabinoid system modulator. ABX-1431 was discovered with Abide,s ... drug candidates that target serine hydrolases, a large ... human physiology and disease. "This is ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 2Abide Therapeutics Announces First Subject Dosed in First-in-Human Clinical Study of ABX-1431, an Investigational Endocannabinoid System Modulator 3
... 2011 Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, announced today ... of an additional $50 million of the company,s shares ... authorization, the total amount available for share repurchases by ...
... University of California San Diego Extension Certificate Program in ... seminar from 5 to 7 pm Thursday, December 8 ... The seminar on conducting clinical trials in Latin America, ... but advance registration is required. The certificate ...
Cached Medicine Technology:Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 2Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program 3UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 2UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana 3
(Date:7/7/2015)... (PRWEB) , ... July 07, ... ... a leading provider of unified communication management solutions, has announced the release ... Select. , This service pack includes a number of enhancements to the ...
(Date:7/7/2015)... ... 2015 , ... On May 29, 2015, Health Canada announced that they had ... claims for gluten free oats and foods that contain them as ingredients. , “We ... (GFCP) to include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory ...
(Date:7/7/2015)... ... ... is holding an onsite job fair to hire 400 people for its new site in ... Wednesday, July 8, and Thursday, July 9, from 9:00 a.m. – 5:00 p.m. , During ... as holding onsite interviews. Interested parties are encouraged to attend the job fair or ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... they have been selected by the Department of Vermont Health Access to provide ... Management Information System (MMIS) and Integrated Contact Center System project. , Vermont is ...
(Date:7/6/2015)... Los Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... resource for finding medical providers for personal injury victims. Throughout the company’s history ... that collectively deliver the care victims need in their recovery. And while Doctors ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... CHICAGO June 6, 2011 An analysis linking ... nearly 232,000 adult cancer cases in western Washington during ... survival: Insolvency rates increase along with the length of ... financial stress due to income loss and out-of-pocket costs ...
... proteins in frog skins which could be used to ... the growth of blood vessels. The award-winning research, led ... has identified two proteins, or ,peptides, which can be ... ,angiogenesis, the process by which blood vessels grow ...
... 7, 2011 The discovery of a potential new ... team has been awarded Project of the Year by ... which began in 2002 under the direction of Dr. ... enzyme that the malaria parasite requires for survival. The ...
... MONDAY, June 6 (HealthDay News) -- Though it,s not clear ... a new study says that men who bully others during ... wives and girlfriends. "It helps people think of bullying ... G. Silverman, an associate professor at the Harvard School of ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
... News) -- Many people who suffer from obstructive sleep apnea ... weight, a new study suggests. Without realizing it, ... night as they struggle to breathe. The condition can cause ... are treated with continuous positive airway pressure (CPAP), a treatment ...
Cached Medicine News:Health News:Study finds bankruptcy rates among cancer patients increase along with survival time 2Health News:Scientists unlock potential of frog skin to treat cancer 2Health News:UT Southwestern research team's anti-malarial work wins international Project of the Year award 2Health News:Boys Who Bully May Grow Up to Be Abusive Men 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2Health News:Weight Loss May Help Sleep Apnea Symptoms 2
Facial Wrap...
Very compressive support for submental liposuction...
Ideal for autoplasty and liposuction of chin and cheeks...
Four way compression with simple contact closure...
Medicine Products: